



# GESUNDHEIT

## 4. AUSSCHREIBUNG

7. EU-RAHMENPROGRAMM FÜR FORSCHUNG, TECHNOLOGISCHE ENTWICKLUNG UND DEMONSTRATION (2007-2013)

**Veröffentlichung:** 30. Juli 2009

**Einreichfristen:**

<b>FP7-HEALTH-2010-single-stage:</b>	<b>19. November 2009</b>
<b>FP7-HEALTH-2010- two-stage:</b>	<b>1. Stufe 29. Oktober 2009, 2. Stufe März 2010</b>
<b>FP7- AFRICA-2010:</b>	<b>14. Jänner 2010</b>
<b>FP7-INFLUENZA-2010:</b>	<b>29. Oktober 2009</b>
<b>FP7-ERANET-2010-RTD:</b>	<b>19. Jänner 2010</b>
<b>FP7-HEALTH-2010-Alternative-Testing:</b>	<b>3. Februar 2010</b>

### 1. BIOTECHNOLOGY, GENERIC TOOLS AND MEDICAL TECHNOLOGIES FOR HUMAN HEALTH

#### 1.1. High-throughput research

Topics for FP7-HEALTH-2010-single-stage submission and evaluation

HEALTH.2010.1.1-1	Harmonisation of phenotyping and biosampling for human large-scale research biobanks
HEALTH.2010.1.1-3	High-throughput analysis of post-translational modifications of proteins

Topics for FP7-ERANET-2010-RTD submission and evaluation

HEALTH.2010.1.1-2	Genomics and Genetic Epidemiology of Multifactorial Diseases
-------------------	--

#### 1.2 Detection, diagnosis and monitoring

Topic for FP7-HEALTH-2010-two-stage submission and evaluation; deadline 1st stage: 29.10.2009

HEALTH.2010.1.2-1	Tools for the identification and the detection of biomarkers in clinical samples and patients
-------------------	---

Topics for FP7-HEALTH-2010-single-stage submission and evaluation

HEALTH.2010.1.2-2	Stratification approaches and methodologies to select from a wide range of biomarkers relevant candidates for clinical validation.
HEALTH.2010.1.2-3	Harmonization, validation and standardisation in genetic testing
HEALTH.2010.1.2-4	Early events in acute hepatitis C virus (HCV) infection with the aim to identify new biomarkers

#### 1.3 Suitability, safety, efficacy of therapies

See: 4.2. Responding to EU policy needs

#### 1.4 Innovative therapeutic approaches and interventions

Topics for FP7-HEALTH-2010-single-stage submission and evaluation

HEALTH.2010.1.4-1	Translational research on cell-based immunotherapy
-------------------	--

## **2. TRANSLATING RESEARCH FOR HUMAN HEALTH**

### **2.1. Integrating biological data and processes: large-scale data gathering, systems biology**

#### **2.1.1. Large-Scale Data Gathering**

Topics for FP7-HEALTH-2010-single-stage submission and evaluation

- HEALTH.2010.2.1.1-1 Large-scale efforts in mouse functional genomics to determine the functions of genes and their involvement in disease
- HEALTH.2010.2.1.1-2 Coordination action(s) on standards in large scale data gathering

#### **2.1.2. Systems Biology**

Topics for FP7-HEALTH-2010-two-stage submission and evaluation; deadline 1st stage: 29.10.2009

- HEALTH.2010.2.1.2-1 Tackling Human Diseases through Systems Biology Approaches
- HEALTH.2010.2.1.2-2 Establishing the foundations to enable systems biology of complex biological processes relevant to human health

Topics for FP7-HEALTH-2010-single-stage submission and evaluation

- HEALTH.2010.2.1.2-3 Developing new and improving existing mathematical algorithms for systems biology

### **2.2. Research on the brain and related diseases, human development and ageing**

#### **2.2.1. Brain and brain-related diseases**

Area 2.2.1 is expected to open at a later stage (end 2009/beginning 2010).

Under area 4.2 of the HEALTH-2010 work programme, under topic HEALTH-2010.4.2-8, the Commission will support as Coordination action a common research initiative for combating neurodegenerative diseases, in particular Alzheimer's disease, implemented by Joint Programming.

#### **2.2.2. Human development and ageing**

Topics for FP7-HEALTH-2010-two-stage submission and evaluation; deadline 1st stage: 29.10.2009

- HEALTH.2010.2.2.2-1 Role of early-life developmental processes in longevity determination
- HEALTH.2010.2.2.2-2 Homeostasis in human development and its effects on lifespan
- HEALTH.2010.2.2.2-3 Integrative systems biology and comparative genomics for studying human ageing
- HEALTH.2010.2.2.2-4 Markers of cellular senescence for human ageing

Topics for FP7-HEALTH-2010-single-stage submission and evaluation

- HEALTH.2010.2.2.2-5 Frailty and its implications in modern society

### **2. 3. Translational research in major infectious diseases: to confront major threats to public health**

#### **2.3.1. Anti-microbial drug resistance**

CLOSED in WP 2010

### 2.3.2. HIV/AIDS, malaria and tuberculosis

#### Topics for FP7-HEALTH-2010-single-stage submission and evaluation

HEALTH.2010.2.3.2-1	Target characterisation and hit-to-lead progression in tuberculosis (TB) Drug development
HEALTH.2010.2.3.2-2	Lead optimisation and late preclinical development in TB drugs
HEALTH.2010.2.3.2-3	European network of cohort studies on HIV/AIDS

#### Topics for FP7-AFRICA-2010 submission and evaluation

HEALTH.2010.2.3.2-4	Controlling malaria by hitting the vector: New or Improved Vector Control Tools
---------------------	---

### 2.3.3. Potentially new and re-emerging epidemics

#### Topics for FP7-HEALTH-2010-single-stage submission and evaluation

HEALTH.2010.2.3.3-1	Biology and control of vector-borne infections in Europe
HEALTH.2010.2.3.3-2	Drug lead discovery against RNA viruses
HEALTH.2010.2.3.3-3	Integrated disease-specific research on West Nile Virus infections, Chikungunya and/or Crimean Congo Haemorrhagic Fever

#### Topics for FP7-INFLUENZA-2010 submission and evaluation

HEALTH.2010.2.3.3-4	Novel therapeutics against influenza
---------------------	--------------------------------------

### 2.3.4. Neglected infectious diseases

#### Topics for FP7-HEALTH-2010-single-stage submission and evaluation

HEALTH.2010.2.3.4-1	Vaccines for childhood bacterial diarrhoeal diseases
HEALTH.2010.2.3.4-2	Comprehensive control of Neglected Infectious Diseases (NID)
HEALTH.2010.2.3.4-3	Next generation of researchers for Neglected Infectious Diseases

## 2.4. Translational research in other major diseases

### 2.4.1. Cancer

#### Topics for FP7-ERANET-2010-RTD submission and evaluation

HEALTH.2010.2.4.1-1	ERA-NET on translational cancer research in Europe
---------------------	--

#### Topics for FP7-HEALTH-2010-single-stage submission and evaluation

HEALTH.2010.2.4.1-2	Structuring translational cancer research between cancer research centres in Europe
HEALTH.2010.2.4.1-3	Structuring clinical research in paediatric and adolescent oncology in Europe

#### Topics for FP7- AFRICA-2010 submission and evaluation

HEALTH.2010.2.4.1-4	Infectious agents and cancer in Africa
---------------------	--

#### Topics for FP7-HEALTH-2010-two-stage submission and evaluation; deadline 1st stage: 29.10.2009

HEALTH.2010.2.4.1-5	Structuring clinical research on rare cancers in adults
HEALTH.2010.2.4.1-6	Translational research on cancers with poor prognosis
HEALTH.2010.2.4.1-7	Predicting long-term side effects to cancer therapy
HEALTH.2010.2.4.1-8	Predicting individual response and resistance to cancer therapy
HEALTH.2010.2.4.1-9	Optimising the delivery of (chemo)radiotherapy and/or surgery to cancer patients

#### **2.4.2. Cardiovascular diseases**

##### Topics for FP7-HEALTH-2010-single-stage submission and evaluation

HEALTH.2010.2.4.2-1	Reducing in-stent thrombosis
HEALTH.2010.2.4.2-2	New approaches to reduce ischemic damage to the heart
HEALTH.2010.2.4.2-3	Identifying new therapeutic targets in atrial fibrillation
HEALTH.2010.2.4.2-4	Diastolic heart failure

#### **2.4.3. Diabetes and obesity**

CLOSED for WP 2010

#### **2.4.4. Rare diseases**

##### Topics for FP7-HEALTH-2010-single-stage submission and evaluation

HEALTH.2010.2.4.4-1	Clinical development of substances with a clear potential as orphan drugs
---------------------	---

##### Topics for FP7-ERANET-2010-RTD submission and evaluation

HEALTH.2010.2.4.4-2	ERA-Net on rare diseases
---------------------	--------------------------

#### **2.4.5. Other chronic diseases**

##### Topics for FP7-HEALTH-2010-single-stage submission and evaluation

HEALTH.2010.2.4.5-1	Investigation of the mechanisms of initiation of allergic response, genetic predisposition, biomarkers and identification of targets for therapy
HEALTH.2010.2.4.5-2	Infection and dysbiosis as the triggers of the development of inflammatory processes in allergies and autoimmune diseases

### **3. OPTIMISING THE DELIVERY OF HEALTHCARE TO EUROPEAN CITIZENS**

#### **3.1. Translating the results of clinical research outcome into clinical practice including better use of medicines, and appropriate use of behavioural and organisational interventions and new health therapies and technologies**

##### Topics for FP7-HEALTH-2010-two-stage submission and evaluation; deadline 1st stage: 29.10.2009

HEALTH.2010.3.1-1	Better understanding of dissemination and implementation strategies
-------------------	---

#### **3.2. Quality, efficiency and solidarity of healthcare systems including transitional health systems**

##### Topics for FP7-HEALTH-2010-single-stage submission and evaluation

HEALTH.2010.3.2-1	Financing systems' effect on quality of healthcare
HEALTH.2010.3.2-2	Risk adjustment algorithms for better health insurance coverage

#### **3.3. Enhanced health promotion and disease prevention**

CLOSED for WP 2010

### 3.4. International public health & health systems

#### Topics for FP7-AFRICA-2010 submission and evaluation

HEALTH.2010.3.4-1	Develop and assess key interventions and policies to address the human resource crisis in the health sector
HEALTH.2010.3.4-2	Feasibility and community effectiveness of innovative intervention packages for maternal and new-born health in Africa
HEALTH.2010.3.4-3	Building sustainable capacity for research for health in Africa
HEALTH.2010.3.4-4	Assessment of migrants' health, disease patterns and impact on health systems

#### Topics for FP7-HEALTH-2010-single-stage submission and evaluation

HEALTH.2010.3.4-5	Assessment of migrants' health, disease patterns and impact on health systems
HEALTH.2010.3.4-6	Impact and cost-effectiveness of existing major health programmes
HEALTH.2010.3.4-7	Financing models for accessible health care

## 4. OTHER ACTIONS ACROSS THE HEALTH THEME

### 4.1. Coordination and support actions across the theme

#### Topics for FP7-HEALTH-2010-single-stage submission and evaluation

HEALTH.2010.4.1-1	Promoting participation of high-technology research-intensive SMEs, operating in the Health sector
-------------------	--

### 4.2. Responding to EU policy needs

#### Topics for FP7-HEALTH-2010-single-stage submission and evaluation

HEALTH.2010.4.2-1	Off-Patent Medicines for Children
HEALTH.2010.4.2-2	International Paediatric initiative
HEALTH.2010.4.2-3	Adverse Drug Reaction Research
HEALTH.2010.4.2-4	International Pluripotent Stem Cell Registry
HEALTH.2010.4.2-5	Methodology to evaluate and monitor implementation and performance of EU funded interventions in developing countries
HEALTH.2010.4.2-6	Impact of EU legislation on health research
HEALTH.2010.4.2-7	International forum for European life sciences funders and performers
HEALTH-2010.4.2-8	Coordination action in support of the implementation by participating States of a Joint Programming Initiative for combating neurodegenerative diseases, in particular Alzheimer's disease

#### Topic for FP7-HEALTH-2010-Alternative-Testing submission and evaluation

HEALTH.2010.4.2-9	<i>Towards the replacement of repeated dose systemic toxicity testing in human safety assessment =&gt; 7 Topics are open:</i>
HEALTH.2010.4.2.9-1	Optimisation of current methodologies and development of novel methods to achieve functional differentiation of human-based target cells in vitro
HEALTH.2010.4.2.9-2	Exploitation of organ-simulating cellular devices as alternatives for long-term toxicity testing
HEALTH.2010.4.2.9-3	Establishment of endpoints and intermediate markers in human-based target cells with relevance for repeated dose systemic toxicity testing
HEALTH.2010.4.2.9-4	Computational modelling and estimation techniques
HEALTH.2010.4.2.9-5	Systems biology for the development of predictive causal computer models
HEALTH.2010.4.2.9-6	Integrated data analysis and servicing
HEALTH.2010.4.2.9-7	Coordination project

## ART DER FÖRDERUNG UND FÖRDERHÖHE

- **Forschungsprojekte:**
  - Forschungsaktivitäten: 50-75 % der förderungswürdigen Kosten, je nach Organisation
  - Demonstrationsaktivitäten: max. 50 % der förderungswürdigen Kosten
  - Management, andere Aktivitäten: max. 100 % der förderungswürdigen Kosten
- **Koordinierungs- und Unterstützungsmaßnahmen:** max. 100 % des Budgets

**Wichtig: Vergessen Sie nicht die Möglichkeit einer Anbahnungsfinanzierung!**

<http://rp7.ffg.at/anbahnungsfinanzierung>

## LINKS

<http://rp7.ffg.at/health>

<http://cordis.europa.eu/fp7/health>

**Österreichische Kompetenzkataloge:**

<http://www.lifesciencesdirectory.at>

## KONTAKT

**Dr. Astrid Hoebertz – Nationale Kontaktstelle**

Tel.: +43 (0)5 7755 – 4104

E-mail: [astrid.hoebertz@ffg.at](mailto:astrid.hoebertz@ffg.at)

**Dr. Ylva Huber**

Tel.: +43 (0)5 7755 – 4102

E-mail: [ylva.huber@ffg.at](mailto:ylva.huber@ffg.at)

**Elke Wenzl**

Tel.: +43 (0)5 7755 – 4111

E-mail: [elke.wenzl@ffg.at](mailto:elke.wenzl@ffg.at)

Informationsstand 30.Juli 2009 - alle Angaben ohne Gewähr